These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18054258)

  • 1. Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention.
    Meikle PJ; Whitfield PD; Rozaklis T; Blacklock D; Duplock S; Elstein D; Zimran A; Mengel E; Cannell P; Hopwood JJ; Fuller M
    Blood Cells Mol Dis; 2008; 40(3):420-7. PubMed ID: 18054258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gaucher disease: a model disorder for biomarker discovery.
    Boot RG; van Breemen MJ; Wegdam W; Sprenger RR; de Jong S; Speijer D; Hollak CE; van Dussen L; Hoefsloot HC; Smilde AK; de Koster CG; Vissers JP; Aerts JM
    Expert Rev Proteomics; 2009 Aug; 6(4):411-9. PubMed ID: 19681676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity.
    Whitfield PD; Nelson P; Sharp PC; Bindloss CA; Dean C; Ravenscroft EM; Fong BA; Fietz MJ; Hopwood JJ; Meikle PJ
    Mol Genet Metab; 2002 Jan; 75(1):46-55. PubMed ID: 11825063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease.
    Altarescu G; Zimran A; Michelakakis H; Elstein D
    Cytokine; 2005 Jul; 31(2):149-52. PubMed ID: 15919211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.
    Ghauharali-van der Vlugt K; Langeveld M; Poppema A; Kuiper S; Hollak CE; Aerts JM; Groener JE
    Clin Chim Acta; 2008 Mar; 389(1-2):109-13. PubMed ID: 18164265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.
    Mirzaian M; Wisse P; Ferraz MJ; Gold H; Donker-Koopman WE; Verhoek M; Overkleeft HS; Boot RG; Kramer G; Dekker N; Aerts JM
    Blood Cells Mol Dis; 2015 Apr; 54(4):307-14. PubMed ID: 25842368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between the biochemical properties of plasma chitotriosidase from normal individuals and from patients with Gaucher disease, GM1-gangliosidosis, Krabbe disease and heterozygotes for Gaucher disease.
    Wajner A; Michelin K; Burin MG; Pires RF; Pereira ML; Giugliani R; Coelho JC
    Clin Biochem; 2007 Mar; 40(5-6):365-9. PubMed ID: 17291472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative evaluation of sphingomyelin and glucosylceramide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard. Practical application to tissues from patients with Niemann-Pick disease types A and C, and Gaucher disease.
    Fujiwaki T; Tasaka M; Yamaguchi S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(2):170-6. PubMed ID: 18502707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
    Hollak CE; van Weely S; van Oers MH; Aerts JM
    J Clin Invest; 1994 Mar; 93(3):1288-92. PubMed ID: 8132768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.
    Dekker N; van Dussen L; Hollak CE; Overkleeft H; Scheij S; Ghauharali K; van Breemen MJ; Ferraz MJ; Groener JE; Maas M; Wijburg FA; Speijer D; Tylki-Szymanska A; Mistry PK; Boot RG; Aerts JM
    Blood; 2011 Oct; 118(16):e118-27. PubMed ID: 21868580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The biochemical diagnosis of Gaucher disease].
    Yargui L; Mokhtari S; Arab M; Berhoune A
    Arch Pediatr; 2005 Aug; 12(8):1301-9. PubMed ID: 15878824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in chitotriosidase values measured on simultaneous samples by two commercial laboratories.
    Sirrs S; Casey R; Patterson MA; McNeil C; Paquin W; Amato D
    Am J Hematol; 2013 Nov; 88(11):980. PubMed ID: 23861203
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography-tandem mass spectrometry.
    Byeon SK; Lee JY; Lee JS; Moon MH
    J Chromatogr A; 2015 Feb; 1381():132-9. PubMed ID: 25597892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The possibility of increasing the precision of biochemical diagnostics of Gaucher disease].
    Horovenko NH; Drozdova VD; Nedoboĭ AM; Ol'khovych NV; Pichkur NO; Tsyhankova MA; Radzikhovs'ka OV
    Tsitol Genet; 2006; 40(3):67-71. PubMed ID: 16933855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.
    Di Rocco M; Giona F; Carubbi F; Linari S; Minichilli F; Brady RO; Mariani G; Cappellini MD
    Haematologica; 2008 Aug; 93(8):1211-8. PubMed ID: 18603565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmalogen levels in Gaucher disease.
    Moraitou M; Dimitriou E; Zafeiriou D; Reppa C; Marinakis T; Sarafidou J; Michelakakis H
    Blood Cells Mol Dis; 2008; 41(2):196-9. PubMed ID: 18501647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced calcium release in the acute neuronopathic form of Gaucher disease.
    Pelled D; Trajkovic-Bodennec S; Lloyd-Evans E; Sidransky E; Schiffmann R; Futerman AH
    Neurobiol Dis; 2005 Feb; 18(1):83-8. PubMed ID: 15649698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease.
    Fuller M; Rozaklis T; Lovejoy M; Zarrinkalam K; Hopwood JJ; Meikle PJ
    Mol Genet Metab; 2008 Apr; 93(4):437-43. PubMed ID: 18162427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S; Roberts A; Patterson MA; Amato D
    Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
    Erikson A; Forsberg H; Nilsson M; Aström M; Månsson JE
    Acta Paediatr; 2006 Mar; 95(3):312-7. PubMed ID: 16497642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.